These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16896073)

  • 21. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines for pandemic influenza. Preface.
    Compans RW; Orenstein WA
    Curr Top Microbiol Immunol; 2009; 333():v-viii. PubMed ID: 19787865
    [No Abstract]   [Full Text] [Related]  

  • 24. Achieving clinical equality in an influenza pandemic: patent realities.
    Kane EM
    Seton Hall Law Rev; 2009; 39(4):1137-72. PubMed ID: 20718133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National plan for pandemic flu unveiled.
    Mitka M
    JAMA; 2006 Jun; 295(23):2707-8. PubMed ID: 16788118
    [No Abstract]   [Full Text] [Related]  

  • 27. Vaccines for pandemic influenza.
    Luke CJ; Subbarao K
    Emerg Infect Dis; 2006 Jan; 12(1):66-72. PubMed ID: 16494720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccines for pandemic influenza: summary of recent clinical trials.
    Keitel WA; Atmar RL
    Curr Top Microbiol Immunol; 2009; 333():431-51. PubMed ID: 19768418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pandemic unpreparedness?
    Nat Rev Microbiol; 2007 Jan; 5(1):2. PubMed ID: 17171851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H5N1 vaccines: how prepared are we for a pandemic?
    Stephenson I
    Lancet; 2006 Sep; 368(9540):965-6. PubMed ID: 16980092
    [No Abstract]   [Full Text] [Related]  

  • 31. Progress with human H5N1 vaccines: a perspective from industry.
    Palache B; Krause R
    Expert Rev Vaccines; 2009 Apr; 8(4):391-400. PubMed ID: 19348556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H5N1 viruses and vaccines.
    Subbarao K; Luke C
    PLoS Pathog; 2007 Mar; 3(3):e40. PubMed ID: 17335350
    [No Abstract]   [Full Text] [Related]  

  • 33. H5N1 vaccine hits the target, but not the bull's eye.
    Sambhara S; Bridges CB; Poland GA
    Lancet Infect Dis; 2007 Aug; 7(8):503-5. PubMed ID: 17646023
    [No Abstract]   [Full Text] [Related]  

  • 34. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
    Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
    Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H5N1 avian influenza: first steps towards development of a human vaccine.
    Wkly Epidemiol Rec; 2005 Aug; 80(33):277-8. PubMed ID: 16171030
    [No Abstract]   [Full Text] [Related]  

  • 37. Influenza vaccines: the good, the bad, and the eggs.
    Schultz-Cherry S; Jones JC
    Adv Virus Res; 2010; 77():63-84. PubMed ID: 20951870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009.
    Hayden FG; Howard WA; Palkonyay L; Kieny MP
    Vaccine; 2009 Jun; 27(31):4079-89. PubMed ID: 19406184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preparing for a possible pandemic: influenza A/H5N1 vaccine development.
    Keitel WA; Atmar RL
    Curr Opin Pharmacol; 2007 Oct; 7(5):484-90. PubMed ID: 17644429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.